A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine

Neurobiology of Disease

Volumn 50, Issue 1, 2013, Pages 49-58

  Urrutia, Andres ^a   Rubio Araiz, Ana ^a   Gutierrez Lopez, Maria Dolores ^a   ElAli, Ayman ^b,c   Hermann, Dirk M ^b   O'Shea, Esther ^a   Colado, Maria Isabel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

Blood brain barrier; Hyperthermia; IgG; JNK; Laminin; Metalloproteinases; Methamphetamine

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BATIMASTAT; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN G; LAMININ; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER DISRUPTION; BLOOD BRAIN BARRIER LEAKAGE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERTHERMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

ANIMALS; ANTHRACENES; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CENTRAL NERVOUS SYSTEM STIMULANTS; ENZYME INHIBITORS; LAMININ; MALE; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METHAMPHETAMINE; MICE; MICE, INBRED C57BL;

EID: 84868225756     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.10.006     Document Type: Article

References (58)

1. Ares-Santos S., Granado N., Oliva I., O'Shea E., Martin E.D., Colado M.I., Moratalla R. Dopamine D(1) receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol. Dis. 2012, 45:810-820.
2. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13681-13686.
3. Bonoiu A., Mahajan S.D., Ye L., Kumar R., Ding H., Yong K.T., Roy I., Aalinkeel R., Nair B., Reynolds J.L., Sykes D.E., Imperiale M.A., Bergey E.J., Schwartz S.A., Prasad P.N. MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009, 1282:142-155.
4. Bowyer J.F., Ali S. High doses of methamphetamine that cause disruption of the blood-brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 2006, 60:521-532.
5. Bowyer J.F., Robinson B., Ali S., Schmued L.C. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse 2008, 62:193-204.
6. Conant K., Lonskaya I., Szklarczyk A., Krall C., Steiner J., Maguire-Zeiss K., Lim S.T. Methamphetamine-associated cleavage of the synaptic adhesion molecule intercellular adhesion molecule-5. J. Neurochem. 2011, 118:521-532.
7. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
8. ElAli A., Urrutia A., Rubio-Araiz A., Hernandez-Jimenez M., Colado M.I., Doeppner T.R., Hermann D.M. Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication. Stroke 2012, 43:1647-1653.
9. Eynott P.R., Xu L., Bennett B.L., Noble A., Leung S.Y., Nath P., Groneberg D.A., Adcock I.M., Chung K.F. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology 2004, 112:446-453.
10. Gonçalves J., Martins T., Ferreira R., Milhazes N., Borges F., Ribeiro C.F., Malva J.O., Macedo T.R., Silva A.P. Methamphetamine-induced early increase of IL-6 and TNF-alpha mRNA expression in the mouse brain. Ann. N. Y. Acad. Sci. 2008, 1139:103-111.
11. Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation 1996, 3:69-75.
12. Granado N., O'Shea E., Bove J., Vila M., Colado M.I., Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 2008, 107:1102-1112.
13. Granado N., Escobedo I., O'Shea E., Colado I., Moratalla R. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008, 62:80-84.
14. Granado N., Ares-Santos S., O'Shea E., Vicario-Abejón C., Colado M.I., Moratalla R. Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration: early loss of TH in striosomes after methamphetamine. Neurotox. Res. 2010, 18:48-58.
15. Granado N., Ares-Santos S., Oliva I., O'Shea E., Martin E.D., Colado M.I., Moratalla R. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol. Dis. 2011, 42:391-403.
16. Gu Z., Cui J., Brown S., Fridman R., Mobashery S., Strongin A.Y., Lipton S.A. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J. Neurosci. 2005, 25:6401-6408.
17. Herron G.S., Banda M.J., Clark E.J., Gavrilovic J., Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J. Biol. Chem. 1986, 261:2814-2818.
18. Hirata H., Cadet J.L. p53-knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J. Neurochem. 1997, 69:780-790.
19. Ho E.L., Josephson S.A., Lee H.S., Smith W.S. Cerebrovascular complications of methamphetamine abuse. Neurocrit. Care 2009, 10:295-305.
20. Hogan K.E., Staal R.G.W., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 2000, 74:2217-2220.
21. Imam S.Z., Newport G.D., Itzhak Y., Cadet J.L., Islam F., Slikker W., Ali S.F. Peroxynitrite plays a role in methamphetamine induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide synthase gene or overexpressing copper-zinc superoxide dismutase. J. Neurochem. 2001, 76:745-749.
22. Indyk J.A., Chen Z.L., Tsirka S.E., Strickland S. Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator/plasmin protease cascade during excitotoxic injury. Neuroscience 2003, 116:359-371.
23. Itzhak Y., Gandia C., Huang P.L., Ali S.F. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamineinduced dopaminergic neurotoxicity. J. Pharmacol. Exp. Ther. 1998, 284:1040-1047.
24. Itzhak Y., Martin J.L., Ali S.F. nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 2000, 11:2943-2946.
25. Kilic E., Spudich A., Kilic U., Rentsch K.M., Vig R., Matter C.M., Wunderli-Allenspach H., Fritschy J.M., Bassetti C.L., Hermann D.M. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008, 131:2679-2689.
26. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802:396-405.
27. Kiyatkin E.A., Sharma H.S. Acute methamphetamine intoxication: brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int. Rev. Neurobiol. 2009, 88:65-100.
28. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 1994, 218:325-329.
29. Krasnova I.N., Cadet J.L. Methamphetamine toxicity and messengers of death. Brain Res. Rev. 2009, 60:379-407.
30. Lee H., Park J.W., Kim S.P., Lo E.H., Lee S.R. Doxycycline inhibits matrix metalloproteinase-9 and laminin degradation after transient global cerebral ischemia. Neurobiol. Dis. 2009, 34:189-198.
31. Lindberg R.L., De Groot C.J., Montagne L., Freitag P., van der Valk P., Kappos L., Leppert D. The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 2001, 124:1743-1753.
32. Liu Y., Brown S., Shaikh J., Fishback J.A., Matsumoto R.R. Relationship between methamphetamine exposure and matrix metalloproteinase 9 expression. Neuroreport 2008, 19:1407-1409.
33. Luo Y., Umegaki H., Wang X., Abe R., Roth G.S. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 1998, 273:3756-3764.
34. Martins T., Baptista S., Gonçalves J., Leal E., Milhazes N., Borges F., Ribeiro C.F., Quintela O., Lendoiro E., López-Rivadulla M., Ambrósio A.F., Silva A.P. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 2011, 1411:28-40.
35. Mizoguchi H., Yamada K., Mouri A., Niwa M., Mizuno T., Noda Y., Nitta A., Itohara S., Banno Y., Nabeshima T. Role of matrix metalloproteinase and tissue inhibitor of MMP in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor down-regulation and dopamine release. J. Neurochem. 2007, 102:1548-1560.
36. Mizoguchi H., Yamada K., Niwa M., Mouri A., Mizuno T., Noda Y., Nitta A., Itohara S., Banno Y., Nabeshima T. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J. Neurochem. 2007, 100:1579-1588.
37. Mizoguchi H., Yamada K., Nabeshima T. Neuropsychotoxicity of abused drugs: involvement of matrix metalloproteinase-2 and -9 and tissue inhibitor of matrix metalloproteinase-2 in methamphetamine-induced behavioral sensitization and reward in rodents. J. Pharmacol. Sci. 2008, 106:9-14.
38. Montaner J., Alvarez-Sabín J., Molina C., Anglés A., Abilleira S., Arenillas J., González M.A., Monasterio J. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001, 32:1759-1766.
39. O'Callaghan J.P., Miller D.B. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 1994, 270:741-751.
40. Oh L.Y., Larsen P.H., Krekoski C.A., Edwards D.R., Donovan F., Werb Z., Yong V.W. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 1999, 19:8464-8475.
41. O'Shea E., Sanchez V., Camarero J., Green A.R., Colado M.I. On the protection against methamphetamine-induced neurotoxicity by benzamide, a PARP inhibitor. Psychopharmacology (Berl) 2003, 165:317-319.
42. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 1998, 152:729-741.
43. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291. (Erratum in: Glia 2002 Oct;40(1):130).
44. Sanchez V., Zeini M., Camarero J., O'Shea E., Bosca L., Green A.R., Colado M.I. The nNOS inhibitor, AR-R17477AR, prevents the loss of NF68 immunoreactivity induced by methamphetamine in the mouse striatum. J. Neurochem. 2003, 85:515-524.
45. Sharma H.S., Ali S.F. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann. N. Y. Acad. Sci. 2006, 1074:198-224.
46. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 1996, 738:172-175.
47. Spudich A., Kilic E., Xing H., Kilic U., Rentsch K.M., Wunderli-Allenspach H., Bassetti C.L., Hermann D.M. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat. Neurosci. 2006, 9:487-488.
48. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
49. Tu Y.F., Tsai Y.S., Wang L.W., Wu H.C., Huang C.C., Ho C.J. Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J. Neuroinflammation 2011, 8:40-55.
50. UNODC World Drug Report 2011, United Nations Publication, Sales No. E.11.XI.10.
51. Wang W., Shi L., Xie Y., Ma C., Li W., Su X., Huang S., Chen R., Zhu Z., Mao Z., Han Y., Li M. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease. Neurosci. Res. 2004, 48:195-202.
52. Wang Y., Zhang Y., Wei Z., Li H., Zhou H., Zhang Z., Zhang Z. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. J. Neurol. Sci. 2009, 285:172-177.
53. Xanthos D.N., Püngel I., Wunderbaldinger G., Sandkühler J. Effects of peripheral inflammation on the blood-spinal cord barrier. Mol. Pain 2012, 8:44.
54. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J. Cereb. Blood Flow Metab. 2007, 27:697-709.
55. Yatsusshige H., Ostrowski R.P., Tsubokawa T., Colohan A., Zhang J.H. Role of c-Jun N-terminal Kinase in early brain injury after subarachnoid hemorrhage. J. Neurosci. Res. 2007, 85:1436-1448.
56. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., Hoshii Y., Tanaka N., Ricci R., Ishihara T., Esato K., Hamano K., Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11:1330-1338.
57. Zhou J., Li J., Rosenbaum D.M., Barone F.C. Thrombopoietin protects the brain and improves sensorimotor functions: reduction of stroke-induced MMP-9 upregulation and blood-brain barrier injury. J. Cereb. Blood Flow Metab. 2011, 31:924-933.
58. Zuo J., Ferguson T.A., Hernandez Y.J., Stetler-Stevenson W.G., Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J. Neurosci. 1998, 18:5203-5211.